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Abstract
Background: Over 95% of rare diseases lack treatments despite many successful treatment studies in animal
models. To improve access to treatments, the Accelerated Approval (AA) regulations were implemented allowing
the use of surrogate endpoints to achieve drug approval and accelerate development of life-saving therapies.
Many rare diseases have not utilized AA due to the difficulty in gaining acceptance of novel surrogate endpoints in
untreated rare diseases.
Methods: To assess the potential impact of improved AA accessibility, we devised clinical development programs
using proposed clinical or surrogate endpoints for fifteen rare disease treatments.
Results: We demonstrate that better AA access could reduce development costs by approximately 60%, increase
investment value, and foster development of three times as many rare disease drugs for the same investment.
Conclusion: Our research brings attention to the need for well-defined and practical qualification criteria for the
use of surrogate endpoints to allow more access to the AA approval pathway in clinical trials for rare diseases.
Keywords: Accelerated approval, Rare diseases, Drug development, Surrogate endpoint, Clinical trials
Introduction
Patients with rare diseases have had difficulty obtaining
disease-specific treatments due to inadequate biotech-
nology investment despite the existence of promising
science. The 1983 Orphan Drug Act was passed to
address this problem, offering financial incentives to
companies developing rare disease drugs. During the
first 25 years since the passage of the Act, 1,892 drugs
were given orphan designation, 326 of which have been
approved [1]. While this astounding success has signifi-
cantly impacted rare disease-affected patients, 95% of
over 6,000 rare diseases still have no specific treatment.
Although there are numerous challenges in develop-
ment of a disease treatment, the most critical is the clin-
ical study process. By law, all drugs must undergo
clinical trial testing to demonstrate safety and
substantial efficacy before FDA approval. This process
usually requires a Phase 3, double-blind, placebo-con-
trolled trial, widely regarded as the “gold standard.”
Phase 3 trials typically assess efficacy using a measure of
clinical benefit such as how a patient feels, functions, or
survives [2]. For disorders with very few and variable
patients or lengthy time courses or irreversible disease
progression, the use of clinical measures as endpoints
can make specific treatment development intractable for
practical and ethical reasons.
The Accelerated Approval (AA) regulations were pro-
mulgated by FDA in 1992 to drive the development of
new treatments for serious and life-threatening disor-
ders, primarily motivated by the AIDS crisis and the
slow pace of treatment development for HIV infection
[3]. In HIV, monitoring death rate or complex endpoints
such as hospitalization for opportunistic infections was
difficult or unethical. Consequently, AA regulations
allowed for drug approval based on the use of surrogate
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[3] - a surrogate endpoint being a measure, such as a
blood test or urine marker, believed to be indicative of a
disease state and treatment effect, but not demonstrative
of a direct health gain to the patient.
AA has been enormously successful at driving innova-
tion in the development of cancer and HIV therapies
during the first 16 years: 26 new chemical entity (NCE)
cancer drugs have been approved, using either tumor
load or progression-free survival as surrogate endpoints,
a n d2 9H I Vd r u g s( 2 5N C E sa n d4c o m b i n a t i o nd r u g s )
have gained approval using either CD4 count or viral
load as endpoints [4]. In the case of HIV, using survival
as an endpoint would have made drug trials too time-
consuming due to the lengthy disease course, too costly
due to the high number of required patients, and
unethical due to the use of placebo in a lethal condition.
Even more critical for the development of HIV treat-
ment was the ability to test the complex combinations
of drugs responsible for the substantial improvement in
long-term outcome. Drug combination studies would
have been impossible using a clinical endpoint given
large patient numbers and extended study lengths,
despite the fact that drug combinations are now essen-
tial to the HIV treatment process. Current HIV thera-
pies are a prime example whereby great scientific ideas
would nonetheless have led to little or no treatment
success without AA access. These successes show that
the AA regulatory pathway is having a profound impact
on innovation in treatment development.
Rare and ultra-rare diseases have not shared in cancer
and HIV’s successes. Only one drug among the 73
NCEs approved under AA, agalsidase beta (Fabrazyme
®), has been used to specifically treat a rare genetic dis-
ease, Fabry [4]. Although treatments for biochemical
genetic diseases, such as urea cycle disorders and phe-
nylketonuria (PKU), have been approved through tradi-
tional FDA pathways using blood test endpoint-driven
trials, the existence of regulatory precedents for approval
(urea cycle drugs), substantial routine disease manage-
ment history, and published study data (PKU drugs),
supported the use of blood test-based endpoints [5,6].
Most ultra-rare diseases do not have the same pre-exist-
ing body of clinical management or historical study data
currently required to utilize the AA pathway. For exam-
ple, during the clinical development of Aldurazyme to
treat mucopolysaccharidosis I (MPS I), there was insuffi-
cient independent clinical data to support the use of the
surrogate endpoint of urine glycosaminoglycan excretion
to predict clinical benefit despite substantial scientific,
animal, and clinical data supporting its relevance
acquired in clinical trials. A second study using clinical
endpoints was required for approval [7,8]. With this
essential requirement for independent clinical data, the
AA pathway is virtually unavailable for novel drugs
developed for untreated ultra-rare diseases.
The European Medicines Agency grants Conditional
Marketing Authorization (CMA), similar to AA, to dis-
ease treatments addressing unmet medical need, includ-
ing orphan diseases. Under CMA guidelines, treatments
are conditionally approved on the basis of a presumed
positive benefit-risk profile, and further confirmatory
studies are agreed upon to establish clinical benefit.
While the use of surrogate endpoints to obtain a CMA
is not explicitly mentioned in legislation, industry has
demonstrated a willingness to cooperate with govern-
ment to make this a reality, and the necessity of colla-
boration between academia, government, and industry
has been foreseen [9,10]. Therefore, the use of surrogate
endpoints to achieve drug approval is a pressing issue in
more than one continent.
Three factors influencing the likelihood of initiation of
a development program for rare disease treatment have
been evaluated recently: prevalence, disease class, and
scientific output. It is less than one-third as likely that a
drug treating an ultra-rare disease with a very low pre-
valence of 0.1 to 9 per 100,000 enters the development
process, as compared to a rare disease having a preva-
lence of 10 to 50 per 100,000 [11]. The authors inter-
preted their finding as an indication that additional
economic incentives and initiatives are necessary to pro-
mote ultra-rare disease treatment development.
We believe improving access to the AA pathway could
potentially fulfill this need. By studying the effect of
increased access to AA for ultra-rare diseases of a speci-
fied disease class and having ample scientific output, our
analysis isolates one of the three factors studied by the
authors: prevalence. We believe that all rare diseases,
even those with more limited research activity or more
poorly understood, would also benefit from this
increased access to the AA pathway, given that a clearer
path to approval will then drive more research in more
productive directions.
To identify scientifically promising disease treatments
that have not translated to human approved use and
which might benefit from access to the AA pathway, we
searched for ultra-rare disease therapies that consistently
reversed disease pathology in animal models, but had
stalled in development. We uncovered numerous exam-
ples of successful treatments, and investigated the prob-
able effect that access to AA would have on investment
potential for their development. After reviewing the dis-
eases and their underlying science, we established rea-
sonable clinical and surrogate endpoints and devised
development programs dependent on both endpoint
types. We demonstrate that improved AA access could
enhance ultra-rare disease treatment feasibility and
investment potential by decreasing the development cost
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increasing potential investment return. We are not veri-
fying or implying that these surrogates have been proven
to be valid, nor at this time are we suggesting methods
to qualify surrogates more efficiently. By highlighting
and quantifying the substantial benefit to development
that we observe, we hope to spur experts in this field to
discuss practical and rational solutions to the challenges
of qualifying surrogates as primary endpoints for pivotal
clinical trials in ultra-rare diseases.
Methods
Literature search
PubMed searches to locate successfully treated animal
models included keywords “disease name,”“ treatment,”
“enzyme replacement therapy,”“ specific name of ther-
apy,” and “animal model.” To confirm lack of FDA drug
approval, the Drugs@FDA database was searched by “dis-
ease name.” Diseases identified are shown in Table 1.
Endpoints
All chosen endpoint values are located in Table 2. The 6
minute walk test (6MWT) was selected as clinical end-
point in the majority of lysosomal storage disorders
(LSDs) exhibiting a varied combination of symptoms.
The Mullen Scales of Early Learning (MSEL) was chosen
as clinical endpoint for the neurological LSDs. An
exception was the selection of the modified Hamburg
LINCL scale, specifically designed to measure neurologi-
cal function in patients with LINCL, which has been
used in the determination of gene therapy efficacy in
this disease [12]. 6MWT and MSEL data is not readily
available for diseases not yet in clinical trials, and thus
predicted 6MWT values were obtained from the Phase
3 MPS I laronidase study [13], and predicted MSEL
values from a study of bone marrow transplants in Hur-
ler patients (personal communication, Dr. Elsa Shapiro).
Conversely, because urinary and CSF marker informa-
tion is more readily available even in diseases without
treatment, an attempt was made to obtain disease-speci-
fic surrogate endpoint values. Urinary and CSF markers
are often presented as a “value in patients,” and a “value
in healthy controls.” In this case, when a value in treated
patients is unavailable, we estimated the ERT treatment
effect to be 60% of total possible improvement. In addi-
tion, standard deviations were reduced such that the
ratio of standard deviation to surrogate value was main-
tained as the value of the surrogate decreased. This was
Table 1 Fifteen rare diseases with potential treatments
Disease class Disease Approx. patient
number
Treatment Pub.
year
Lysosomal storage a-Mannosidosis 200 i.v. a-mannosidase 2004
Aspartylglucosaminuria 400 i.v. glycosyl- asparaginase 2000
Galactosialidosis 100 i.v. PPCA 2004
Mucopolysaccharidosis IV A (MPS IVA) 2,000 i.v. GALNS 2008
Mucopolysaccharidosis VII (MPS VII) 200 i.v. b-glucuronidase 1994
Neurological GM1 Gangliosidosis 850 oral chaperone N-octyl-4-epi-b-
valienamine
2003
Late Infatile Neuronal Ceroid
Lipofuscinosis (LINCL)
600 intraventricular TPP1 2008
Metachromatic Leukodystrophy (MLD) 4,000 intrathecal ASA 2005
Mucopolysaccharidosis IIIA (MPS IIIA) 1,300 intra-CSF sulfamidase 2004
Niemann-Pick B 650 i.v. ASM 2000
Lysosomal Acid Lipase Deficiency
(LAL Deficiency)
150 i.v. mannose-6-phosphate
terminated LAL
2001
Enzyme deficiencies
affecting:
Kidneys Primary Hyperoxaluria 2,400 oral crystalline oxalate-
decarboxylase
1999
Skin and
connective tissue
Recessive Dystrophic Epidermolysis
Bullosa (RDEB)
500 i.d. C7 2004
X-Linked Hypohidrotic Ectodermal
Dysplasia
(X-Linked HED)
700 i.v. EDA1 2003
Carb. metabolism Congenital Disorder of Glycosylation
Ib
(CDG-Ib)
100 oral mannose 1998
The table shows the approximate patient number and treatments, based on literature reviewed and author expertise. Specific disease data obtained from
published articles, references 26, 43-56. Approximate patient number calculation using OMMBID and Orpha.net data, as described in Methods. Eleven of the 15
diseases represent lysosomal storage disorders. The other four are diverse enzyme deficiencies affecting the kidneys, skin and connective tissue, and
carbohydrate metabolism. Proposed treatments for the 15 diseases include protein or substrate replacement, chaperone therapy, metabolic diversion of an
accumulated toxic compound, and enzyme replacement therapies (ERTs).
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tend to decrease as heterogeneous patients are treated
[13,14]. We obtained information in this manner for a-
mannosidosis [15,16], aspartylglucosaminuria [17], galac-
tosialidosis [18], MPS IV A [19], and GM1 gangliosidosis
[20]. Urinary GAG values from the Phase 3 MPS I laroni-
dase study [13] were used to estimate the possible effect
of ERT in MPS VII. Unpublished data was used to esti-
mate brain injury and sulfatide levels in both late infantile
neuronal ceroid lipofuscinosis and metachromatic leuko-
dystrophy. Unpublished values of mean serum pathologic
substrate measured during the laronidase Phase 1/2
study obtained from Zacharon Pharmaceuticals were
used to estimate treatment effect in MPS IIIA.
To test drug efficacy for Niemann-Pick B, we used %
Predicted Forced Vital Capacity [13] as a clinical end-
point since impaired lung function and frequent lung
infections are common in this disease. Niemann-Pick B
patients experience hepatosplenomegaly which can affect
b r e a t h i n gb e c a u s et h el a r g eo r g a n si n f r i n g eu p o ns p a c e
normally inhabited by the lungs. Liver size [21] was
therefore chosen as a potential surrogate endpoint.
In some diseases, clinical endpoints were chosen to
reflect a severe problem faced by patients, namely, survi-
val (LAL Deficiency [22]), renal failure (Primary Hyper-
oxaluria [23]), hospitalizations (RDEB [24] and X-Linked
HED [25]), and episodes of thrombosis (CDG-Ib
[26-30]). Surrogate endpoints were almost always chosen
to relate directly to disease mechanism, and were often
connected to the clinical endpoint: in Primary Hyperox-
aluria, urinary oxalate [31,32] increases risk of renal
stones, which in turn raises risk of renal failure; and in
Congenital Disorder of Glycosylation Ib, episodes of
thrombosis are brought about by a deficiency in antith-
rombin III [33-36] levels. Liver size [21] was chosen as
surrogate endpoint for LAL Deficiency. Number of
anchoring fibrils in biopsy was chosen as surrogate end-
point for RDEB [37].
Table 2 Parameters used in NPV and cost to approval calculations
Clinical Surrogate
Disease Estimated cost
of treatment
Endpoint Sample
size
Time to see
effect
Endpoint Sample
size
Time to see
effect
I/II III, IV I/II I/II III I/II III
a-Mannosidosis $300,000 6 Minute Walk Test
(6MWT) (meters)
12 52 6 mos 6 mos Urinary Man2GlcNAc (mmol/mol
creatinine) measured by HPLC
10 20 3 mos 6 mos
Aspartyl-
glycosaminuria
$300,000 6MWT (meters) 12 45 6 mos 6 mos Urinary aspartylglucosamine
(μmol/mmol creatinine)
6 12 3 mos 6 mos
Galactosialidosis $300,000 6MWT (meters) 12 52 6 mos 6 mos Urinary oligosaccharides (nmol/
mg creatinine)
10 20 3 mos 6 mos
MPS IVA $300,000 6MWT (meters) 20 52 6 mos 6 mos Urinary keratan sulfate (ng/g
creatinine)
15 30 3 mos 6 mos
MPS VII $300,000 6MWT (meters) 10 45 6 mos 6 mos Urinary GAG (μg/mg creatinine) 6 12 3 mos 6 mos
GM1
Gangliosidosis
$120,000 Mullen Scales of Early
Learning (MSEL)
20 127 6 mos 1 yr CSF GM1 ganglioside (pmol/ml) 15 30 3 mos 6 mos
LINCL $200,000 Modified Hamburg
LINCL clinical rating
scale
10 30 6 mos 1 yr CSF neurofilament protein (ng/L) 15 30 3 mos 6 mos
MLD $200,000 MSEL 20 127 6 mos 1 yr CSF sulfatide (nmol/L) 10 30 3 mos 6 mos
MPS IIIA $200,000 MSEL 20 127 6 mos 1 yr CSF MPS (heparan sulfate) 10 30 3 mos 6 mos
Niemann-Pick B $300,000 Forced vital capacity
(FVC %)
10 30 6 mos 6 mos Liver size (% change in liver size
by MRI)
10 30 6 mos 6 mos
LAL Deficiency $300,000 Survival 15 30 6 mos 1.5 yrs Liver size (% change in liver size
by MRI)
10 30 6 mos 6 mos
Primary
Hyperoxaluria
$300,000 Renal failure 20 183 6 mos 2 yrs Urinary oxalate (mg/1.73 m²/day) 10 20 3 mos 6 mos
RDEB $300,000 Hospitalizations 20 61 6 mos 1 yr Number of anchoring fibrils over
2×2 5μm of lamina densa
10 30 3 mos 6 mos
X-Linked HED $100,000 Episodes of severe
illness
20 87 6 mos 1 yr First molar tooth bud presence 10 54 6 mos 6 mos
CDG-Ib $50,000 Thrombosis 10 30 6 mos 1 yr Antithrombin III (%) 6 12 6 mos 6 mos
The table shows the diseases, the estimated cost of therapy, and endpoint and study design information; clinical and surrogate sample size and time to see
effect values, and is based on references 12-39 and authors’ expertise, as described in Methods. Clinical endpoints were chosen from successful development
programs (6 minute walk test (6MWT) [13]), or well-accepted clinical problems (renal failure, hospitalizations, or developmental testing), often indicative of a
disease’s most severe aspect. We chose surrogate endpoints that directly reflected the disease state, and for which the pathologic mechanism was clear; some
surrogates were selected for their conceptual link to a chosen clinical endpoint. These surrogates include urinary or CSF substrate accumulation, measures of
tissue injury, or alteration in major organs.
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the presence of the first molar tooth bud was chosen as
a surrogate endpoint. In the treated canine model [39],
the appearance and number of primary teeth were
unchanged from the untreated model. However, perma-
nent teeth showed dramatic improvement. We postu-
lated that the same phenomenon might hold true in the
treatment of the human disease and chose to measure
the appearance of permanent teeth. Evidence of perma-
nent first molar tooth buds, the earliest of human per-
manent teeth, can be detected by X-ray as early as 6
months after birth.
Minimum and maximum sample sizes and trial lengths
In order to assure the clinical programs had sufficient
safety exposure, a minimum number of patients exposed
was set, particularly in the case of very low patient pre-
valence, or if the treatment effect is expected to be dra-
matic and need too few study patients. Length and
sample size during Phase 3 were primarily determined
by time needed to detect efficacy and sample size
calculations.
Being an exploratory study, Phase 1/2 trial patient
numbers were all set between 6 and 20. The small num-
ber of 6 patients was only assigned in the surrogate end-
point Phase 1/2 trial for diseases with extremely low
prevalence (Aspartylglycosaminuria, MPS VII, and CDG
1b). The larger number of 20 patients was assigned to
those diseases in which the clinical endpoint required
over 60 patients in order to detect efficacy in the Phase
3 trial. Ample time was allotted to establish dosing and
get a better sense of efficacy.
Patient numbers in Phase 3 trials were primarily
determined by sample size calculations. When sample
size needed was low, a minimum of 12 patients for a
urinary marker, and 30 for any other surrogate or clini-
cal marker, was set. Again, the small number of 12 was
reserved for the rarest of diseases. A minimum of 6
months was chosen for a Phase 3 trial to provide ade-
quate safety and exposure information. See Table 2 for
trial times and numbers of patients.
NPV and cost to approval calculation
NPV was calculated by using a template obtained from
Nature Biotechnology [40], which was then modified to
account for a Phase 4 trial in surrogate endpoint devel-
opment models. For simplicity, the orphan drug tax
credit was omitted and no adjustment for risk was
applied. Some key elements of the NPV Calculation are
described below.
Preclinical cost was set at $10 M over 2 years. This
figure includes the cost of development after a product
is identified, and covers pharmacokinetics and toxicol-
ogy studies, pilot formulation work, and minimal drug
production required for an IND filing. Clinical costs
were based on size and length of studies. Common per
patient per year costs were based on study types. The
cost of product manufacturing was built into the cost
per patient number.
Since the NPV spreadsheet was designed to work in
whole years, clinical trial times were averaged to the
nearest whole year, rounding up at the halfway point. In
order to preserve accuracy of cost prediction over
rounded years, the cost estimates during actual trial
lengths were spread out over the rounded trial length.
Annual overhead was set at $2 M, independent of market
size. It should be noted that during Phase 3 and Approval
phases, annual overhead includes the cost of continuing
to treat patients from previous trials in extension studies.
This continued treatment is routinely done in most if not
all rare disease studies. In the post-marketing phase,
patents would certainly stretch out sales beyond that for
orphan drug protection and change the economics. How-
ever, at the decision-making stage for investment in rare
disease treatments, often no patents are available and
compounds are in the public domain so the decision to
invest assumes no patents were in existence. During the
commercial phase, manufacturing, distribution and mar-
keting costs were estimated at 60% of revenue, and this
figure includes post-marketing commitment costs such
as product support and patient registries other than the
AA- related Phase 4 commitment.
Treatment cost selection
Intravenous ERT in the case of severe rare diseases was
estimated at $300,000 while the cost of intrathecal ERT
would approximate $200,000/year, based on current
ERT costs (Table 2). Small-molecule therapy for severe
diseases was estimated to be $120,000, a similar order of
magnitude to miglustat for Gaucher disease type 1 treat-
ment, at about $80,000/year. Mannose for CDG-Ib was
estimated at $50,000/year. Companies were not con-
sulted in these pricing estimates, and they are rough
estimates provided only for relative comparisons.
Revenue determination
The estimated number of patients was multiplied by
price of therapy in order to calculate estimated revenue.
Number of patients was calculated by multiplying inci-
dence rates and average life span. Alternatively, when
patients had been directly counted, this value was multi-
plied by 3, and when there existed a published number
of patients described in the literature, the number of
reported patients was multiplied by 5 to account for
underrepresentation in the literature. To estimate these
values, the OMMBID and Orpha.net were searched.
There is no precise and accurate way to determine mar-
ket size in rare diseases.
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For all determinations of sam p l es i z e ,ap - v a l u eo f0 . 0 5
and a power of 80% were used. When endpoint values
with standard deviations for both untreated and treated
patients, or untreated and control patients, were avail-
able, a two sample t-test analysis was performed [41] to
calculate sample size. If the percentage of patients
experiencing an event or symptom before and after
treatment were given, a comparison of event rates
between two independent cohorts was done [42]. The
result used was the one “assuming outcome data will be
analyzed prospectively by Fisher’s exact-test or with a
continuity corrected chi-squared test [42].” This
assumption was chosen based on small clinical trial size.
For some programs with surrogate endpoints, the study
size estimate based on power calculations would have
been too small for reasonable expectations of safety
exposure, and in these cases, a minimum study size was
applied.
Results
Numerous rare diseases exist with successfully treated
animal models and stalled clinical development
We searched PubMed to locate publications describing
successfully treated animal models with rare disease
treatments not yet approved in the US or EU. These
treatments were either completely stalled in develop-
ment, or are currently in the process of development,
though delayed. Stem cell and gene therapy treatments
were not considered due to the potential complexity of
translation to humans, and instead we focused on pro-
tein or small molecule therapies. Our experiences, as
well as the relative ease of treatment, led us to primarily
focus on inherited disorders of metabolism. Endocrine,
nutritional, and metabolic disease treatments were
found to be among the most likely to have development
programs initiated [11]. We identified 15 diseases having
a relevant corresponding animal model, a treatment
with a known mechanism, and a treatment effect which
appeared to be potentially clinically relevant [26,43-56]
(Table 1). This disease selection is not intended to be an
exhaustive listing of all possible successful treatments in
animal models, but represents a sufficient set of exam-
ples for study.
Comparing cost of development using clinical or
surrogate endpoints
In order to rigorously investigate the differences
between the use of clinical and surrogate endpoints, we
first identified reasonable endpoints for our 15 diseases
(Table 2). We sought and obtained input from experts
to help guide our choice in the determination of both
types of endpoints. All endpoints, their values, expected
treatment effects, and timeframe needed to detect
change can be located in Table 2. Additional details on
endpoint selection are in the online Methods section.
Although we believe that these endpoints are reasonable,
we do not imply that we have singled out the optimal
ones, nor that these endpoints currently meet the quali-
fication criteria a regulatory authority might require for
use in pivotal clinical study. Our aim is to illustrate the
benefit of surrogate endpoint use to demonstrate the
potential value and stimulate discussion of appropriate
qualification criteria.
We constructed three hypothetical development pro-
grams using a standardized framework that remained
constant in order to facilitate direct comparisons. We
then varied clinical trial costs and time, based on each
program’s unique features and endpoints (Figure 1). To
estimate revenue, we established a best estimate of mar-
ket size based on incidence and likely lifespan (Table 1),
and chose market prices for products to be comparable
to those for similar approved treatments (Table 2). All
hypothetical programs were assumed to be successful at
each step, without delays or adverse events, and no
adjustments for risk of failure were made. The program
costs are therefore conservative and represent a best
case scenario.
The first clinical endpoint-based program contains a
Phase 1/2 study in which pharmacokinetics and dosing
are established and a first look at clinical efficacy occurs,
followed by a Phase 3 study; realistic sample sizes and
durations for Phase 3 trials were determined based on
chosen endpoint properties and historical study sizes.
Surrogate-based clinical development programs come in
two forms: one surrogate-based program uses a similar
2-study sequence, and a second program uses a single
study. Because a surrogate endpoint-based study
requires fewer patients and less time to observe treat-
ment effects, the time to enroll patients, treat them, and
conduct analyses is shortened. In this analysis, we
required a minimum study length and minimum patient
enrollment to ensure the collection of sufficient safety
data. The 1-study surrogate endpoint-based program
has a greater risk of failure because there is less prior
clinical experience, less insight into optimal drug dosing,
and a lack of data to inform on the choice of endpoints
and potential treatment effect size, information which
would have been acquired during a Phase 1/2 trial.
However, in the case of a disease with an exceptionally
small patient population and a dramatic clinical or bio-
chemical effect in the treated corresponding animal
model, a single study may be the only financially or
clinically viable option. Both surrogate endpoint pro-
grams include the cost of an additional 2-year post-mar-
keting study comparable in size and cost to Phase 3, as
expected under AA, whereas the clinical endpoint-based
program does not. Post-marketing studies are often
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Figure 1 Three model clinical development programs used to estimate costs. The top program shows a typical abbreviated two study
clinical program as a starting place for analysis. The two study surrogate endpoint study uses the same pre-approval studies but adds a post-
approval Phase 4 study. The third program assumes that a single clinical study would be conducted preapproval and that a Phase 4
confirmatory study would be conducted. Timelines begin once a drug has been developed and shown to be effective in an animal model; a 2-
year preclinical time period follows, during which pharmacology-toxicology studies and clinical drug production are conducted, at a cost of $5
M/year. Clinical trials then occur with time allotted for study startup, enrollment, and discussion with regulatory authorities, followed by a six
month priority review approval process. IND: Investigational New Drug, FPI: First Patient In, LPI: Last Patient In, LPO: Last Patient Out, NDA: New
Drug Application.
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Page 7 of 13required even when a drug has been approved under a
clinical endpoint-based program. We elected to omit
this requirement in our model in order to avoid skewing
financial results too favorably toward the surrogate end-
point-based programs. The net present value of a devel-
opment program, an investment calculation explained
below, is reduced by the addition of the cost of a post-
marketing study. Our three programs represent increas-
ingly aggressive approaches to drug development and
provide us with three points on the cost spectrum.
Financial impact of surrogate versus clinical endpoint-
based clinical development
Clinical development represents both the largest single
expenditure and risk factor in achieving a return on an
investment. By utilizing either a 2-study or 1-study pro-
gram using a surrogate endpoint rather than clinical
endpoint program, we found that cost to approval
decreased by 46% and 62%, respectively (Table 3). The
total cost to approval declined from a mean of $90 M to
$40 M and $28 M, respectively, representing a savings
of $50 M and $62 M over a clinical endpoint-based pro-
gram. All single-study surrogate-based programs were
completed for under $34 M.
The benefit of a decrease in cost to approval is an
increase in the number of drugs brought to approval for
the same investment (Figure 2). The high cost of clinical
endpoint-driven programs results in the development of
only about 11 rare disease drugs for an investment of
$1B, whereas a 2- or 1-study surrogate-based clinical
program would increase this number to 25 and 36
drugs, respectively. Therefore, if we can establish how to
manage reasonable AA access, we can triple the number
of drugs developed and diseases treated for the same
investment.
Investment value of surrogate endpoint-based programs
Net Present Value (NPV) is the dollar amount that
encompasses the overall investment and return for a
program, and is commonly used in industry as a tool to
assess the value of investing in a program. We did not
include an adjustment for the risk of failure, which
would have likely skewed results even more favorably
toward surrogate endpoint use, which have a greater
likelihood for detecting a consistent effect and reducing
NPVs in general.
NPVs increase from a mean of $23 M using a clinical
endpoint design to $53 M and $72 M using a 2- and
Table 3 Cost to approval and NPV calculations and analysis for all three clinical development programs
Cost to approval % Decrease in cost to
approval
Net present value
Disease Clinical (all
values in
millions)
Two-
study
surrogate
One-
study
surrogate
From clinical
to two-study
surrogate
From clinical
to one-study
surrogate
Clinical Two-
study
surrogate
One-
study
surrogate
Difference
between clinical
and one-study
surrogate
a-Mannosidosis 76 42 28 45% 63% (29) (14) (5) 24
Aspartylglucosaminuria 70 32 23 54% 67% (0) 17 28 28
Galactosialidosis 76 42 28 45% 63% (41) (27) (19) 22
MPS IVA 85 53 34 37% 60% 188 201 248 59
MPS VII 68 32 23 52% 66% (24) (8) (1) 23
GM1 Gangliosidosis 80 32 23 59% 71% (16) 9 19 34
LINCL 49 42 28 14% 42% 8 14 28 20
MLD 119 39 28 68% 76% 213 289 342 129
MPS IIIA 119 39 28 68% 76% 19 66 86 67
Niemann-Pick B 56 50 34 10% 39% 39 39 58 19
LAL Deficiency 77 50 34 35% 56% (35) (23) (13) 23
Primary Hyperoxaluria 284 42 28 85% 90% 68 242 290 223
RDEB 105 49 34 54% 68% (14) 18 33 46
X-Linked HED 57 35 27 39% 53% (15) (3) 4 19
CDG-Ib 28 21 17 23% 38% (21) (19) (17) 4
AVERAGE 90 40 28 46% 62% 23 53 72 49
These estimates are for comparison between clinical and surrogate based programs using the NPV spreadsheet in reference 40. The specific value for any
program can be substantially different with different assumptions, however for a comparison, these values were considered reasonable based on author
experience. In this paper, cost to approval represents total cash invested in a development program after a drug is identified and until the pivotal approval event
occurs, when revenue begins. Net present value (NPV) represents a measure of investment return in which the cost of invested capital over time is balanced
against the benefit of future revenue, while adjusting for the time value of money. No adjustment for risk of failure was used to avoid having another
independent variable complicating interpretation. We chose a standard overhead cost of $2 M/year. We then put in place a 4-year ramp to maximal revenuea t
80% of maximum market size. We chose seven years of orphan drug exclusivity, after which we assumed the introduction of a generic that eliminates all further
revenue.
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Page 8 of 131-study surrogate endpoint design, respectively (Table
3). The most significant gains were observed with a 1-
s t u d ys u r r o g a t ec o m p a r e dt oac l i n i c a ls u r r o g a t ep r o -
gram. Fourteen out of 15 NPVs increased by $19 M or
more. Four out of nine which displayed negative values
in a clinical endpoint program changed to positive. Of
the remaining six NPVs, three increased by two-fold or
better with the AA pathway.
Case examples
MPS VII is a lysosomal storage disease and one of the
rarest of our 15 disorders, with only an estimated 200
patients in industrialized nations. The first successful
demonstration of ERT in MPS VII mice showed a sig-
nificant reduction in accumulation of lysosomal storage
in 1994 [52] and many additional papers have since
appeared demonstrating successful enzyme therapy in
MPS VII animals. Three similar MPS disorders, MPS I,
II, and VI, all have approved ERTs, confirming the likely
success of a program for MPS VII. The diseases a-man-
nosidosis, aspartylglucosaminuria, and galactosialidosis
are similar cases. Switching from the 6MWT to a urin-
ary storage marker, the needed number of Phase 3
patients is reduced by at least half, a key consideration
given the rarity of these diseases, and the total time for
development is likely shortened since a broader spec-
trum of patients qualifies for enrollment. The NPV for
ERT in MPS VII is negative for all three models.
However, it approaches a positive value in the 1-study
surrogate endpoint model.
Primary hyperoxaluria results from overproduction of
urine oxalate, leading to kidney stones, loss of kidney
function, and oxalosis, the deposition of calcium oxalate
crystals in the organs. Mice displaying symptoms similar
to primary hyperoxaluria type 1 were treated with an
oxalate-degrading enzyme and exhibited histologically
normal kidneys with no oxalate crystals and normal kid-
ney filtration [57]. In order to detect efficacy by measur-
ing rates of renal failure, the disease’sm o s td a m a g i n g
feature, a two-year study enrolling approximately 183
patients selected for their particular stage of disease
w h e r er e n a lf a i l u r ei sp r o g r e s s i n gw o u l dl i k e l yt a k ea
long time to enroll and conduct. In contrast, reduction
of urinary oxalate is a straightforward measurement that
could take as little as three months and 20 patients to
detect. Far from being an unreliable marker, excessively
high oxalate levels are known to directly damage kid-
neys. In this case, an NPV of $68 M jumps to $242 M
when switching from a clinical endpoint to a 2-study
surrogate endpoint model.
Recessive dystrophic epidermolysis bullosa (RDEB) is a
disease caused by defects in type VII collagen protein
which binds the dermis to the epidermis. Blistering and
sores readily occur, open wounds are slow to heal and
susceptible to infection, esophageal scarring can cause
eating difficulties, and chronic inflammation increases
risk of squamous cell carcinoma. Injection of type VII
collagen in DEB mice corrected the disease phenotype
by decreasing skin fragility, blistering, and prolonging
lifespan [58]. Clinical endpoints might include the rate
of hospitalizations or skin infections, though these end-
points may be confounded by varying clinical practice
or quantities of supportive home care. In contrast, using
a measure of skin adhesion, such as number of anchor-
ing fibrils, or a tension test that would measure adhe-
sion strength between dermis and epidermis, would be a
more direct measure of drug effect. The NPV for type
VII collagen treatment increases from -$14 M to $18 M
and $33 M using the 2-study and 1-study surrogate end-
point model, respectively.
The potential benefit of surrogate markers is particu-
larly critical in neurologic disorders. To detect efficacy
of ERT in the neurological lysosomal storage diseases,
LINCL, MLD, and MPS IIIA, we selected CSF markers
for abnormal brain substrate storage and/or brain injury
as surrogate endpoints since they should represent the
direct adverse impact of storage on brain pathology.
Variability in disease expression, the plasticity and com-
plexity of the nervous system, and the indeterminate
degree of irreversibility make using neurological clinical
endpoints, such as development quotient, challenging. A
surrogate marker of neurologic injury or substrate
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Figure 2 The number of drugs developed with a $1 billion
dollar investment. We used the cost to launch figures to estimate
how many drugs could be developed assuming all programs were
successful, and no programs suffered any delays or problems. The
comparison is a relative comparison. We did not include any risk
factor for the failure of programs, and if they had been added, the
surrogate based program number would have been relatively
higher than the clinical endpoint driven programs.
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chemical effect of treatment in neurologically heteroge-
n e o u sp a t i e n t sa n db eam o r er e l i a b l ew a yt oa s s e s s
treatment benefit.
Discussion
We have located a number of potential treatments for
rare genetic diseases that have yet to be translated to
clinical use due to a number of barriers in development.
By assessing development costs in model development
programs using clinical or surrogate endpoints, we have
demonstrated the potential benefit of increased accessi-
bility to the AA pathway in obtaining rare disease drug
approval. The use of surrogate endpoints brings about
profound changes in cost to approval and NPV. AA
accessibility potentially increases the number of drugs
developed for rare diseases 3-fold for the same invest-
ment, resulting in many more diseases and patients trea-
ted in a more innovative and productive development
system.
Although concern has been raised that orphan pro-
duct costs are very high, and that increasing the
approval rate of drugs might increase health care costs,
we believe that many of these treatments could reduce
some clinical care costs as well and reduce the eco-
nomic impact on families. In addition, as long as devel-
opment costs are extremely high, the costs of drugs will
be driven to stay equally high. By controlling high devel-
opment costs through improved access to AA, orphan
drug cost management is more plausible, without shut-
ting down the incentive for investment in development.
In no case should it be said that blocking the develop-
ment of life-saving, life-changing treatments is an ethical
option to save money on healthcare.
This paper does not aim to prove the merit of the
proposed surrogates, but only shows how the use of sur-
rogate endpoints could impact investment potential.
Improved access to AA depends on whether the surro-
gate can be shown to be “reasonably likely to predict
clinical benefit” [3] by FDA standards. Biotechnology
companies have encountered development difficulties
because of the lack of clear qualification criteria for sur-
rogate endpoints due to the belief that each must be
evaluated on a case-by-case basis. This unpredictable
process significantly hinders the initiation of develop-
ment of many programs that might require a novel sur-
rogate endpoint. As an example, the use of the
surrogate endpoint of kidney biopsy to gain approval for
the treatment of Fabry was initially resisted by FDA,
which sought greater assurance that the pathologic sur-
rogate was predictive of clinically meaningful benefit.
The renal pathology marker for Fabry was eventually
affirmed by the Metabolic and Endocrine Advisory
Committee Meeting in January 2003 [59] and over time,
has been shown to predict clinical outcome in a confir-
matory study. Other examples exist of surrogate end-
points in rare diseases that have substantial animal
model data to support them, but are rejected due to reg-
ulatory uncertainty of their ability to predict clinical out-
come [7,8]. Some uncertainty for surrogates will always
exist in rare diseases with limited patient-based clinical
data. The creation of a precise guidance or established
criteria to support researchers, those involved in treat-
ment development for rare diseases, and investors
would help foster the effective use of appropriate surro-
gates and improve access to the AA pathway.
The use of surrogate endpoints poses a risk for the
approval of ineffective or unexpectedly harmful treat-
ments. This concern has heightened due to recent high
profile failures of large market drugs. Some surrogates
were unable to provide accurate assessments of clinical
benefit or failed to capture adverse effects unrelated to
the drug’s mechanism of action, as in the case of cardiac
arrhythmias or many other diseases [60]. For instance,
encainide and fleicanide were successful in suppressing
arrhythmia, with the intent of decreasing risk of sudden
cardiac death, but were later found to bring about a 3-
fold increase in sudden cardiac death [61]. However,
such cases may not provide an applicable cautionary
example of surrogate use for many life-threatening rare
diseases because many rare biochemical disorders have
far more relevant and direct biochemical or pathologic
markers. These biomarkers are directly related to the
disease pathophysiology and also to the mechanism of
drug action, and so should more accurately assess
whether a drug has a beneficial treatment effect. This
holds true even if the ability of the endpoint to predict
clinical outcome is yet unproven. It is plausible that
some of these drugs may not demonstrate clinical effi-
cacy in Phase 4, but given that the drugs should be rea-
sonably safe through the required clinical evaluation, we
believe that families will accept the possibility that the
drugs’ efficacy may be less than expected. To date, no
rare disease drugs approved on biochemical endpoints
have been withdrawn for lack of efficacy or safety issues.
Our analyses do require minimum patient exposure in
clinical trials to ensure a re a s o n a b l ed e g r e eo fs a f e t y ,
even if efficacy using the surrogate endpoint could be
proven with smaller patient numbers.
Surrogate endpoints are not simply a convenience, but
are a necessary part of the development path for some
ultra-rare disorders. Surrogate endpoints may be indis-
pensable for clinical trials when too few patients exist to
conduct a large clinical endpoint-driven, double-blind
trial. Diseases with substantial heterogeneity or variable
irreversibility of disease symptoms, such as bone or neu-
rologic disease, may also require surrogate endpoint-dri-
ven trials to ever have the chance to be treated. It is
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fested by a variety of symptoms when not every patient
expresses each symptom; those who are not affected in
one aspect of a disease cannot, with therapy, show sub-
stantial improvement in that aspect, even if overall
improvement in health is significant. It is also difficult
to detect drug efficacy in treating diseases with varying
levels of irreversibility, which results when a disease is
diagnosed and treated after chronic tissue damage has
occurred. If a patient has been permanently changed by
disease, a small clinical improvement may appear to be
a failure, even if the degree of improvement was the
maximum possible for that patient. Surrogate endpoints
may be more effective than clinical endpoints in detect-
ing efficacy in these situations because they can indicate
that the drug is having the correct metabolic reversal
effect regardless of the reversibility of the accumulated
clinical disease symptoms. Since patients with some dis-
e a s e ss u c ha sn e u r o l o g i cd i s o r d e r sa r ec o m m o n l yd i a g -
nosed too late in their disease course for effective
disease reversal, the biochemical treatment effect may
be the only readily measurable benefit. Once a drug is
approved, there will be a strong incentive to diagnose
patients earlier in their disease course as a result of the
availability of treatment [62]. Clinical benefit must then
be verified over time by studying early-treated patients
in post-marketing studies over several years. With these
development steps using the AA pathway, a drug can be
developed and the natural history of the rare disease is
forever changed by the approved treatment. This devel-
opment course to early rare disease management can
never be initiated if the first step to treatment approval
via the AA pathway is not taken.
We cannot and should not expect surrogates to accu-
rately and quantitatively predict all clinical outcomes.
The relationship between a blood or urine test and a
clinical outcome will rarely be a perfect linear propor-
tional relationship, nor can a surrogate endpoint quanti-
tatively predict the complex interplay of severity,
progression, and other clinical factors on a given clinical
outcome. The surrogate can provide a clear indication
that the treatment effect is occurring and that the prob-
abilistic outcome of clinical benefit is substantially
improved. A reasonable degree of predictive value and
risk must be determined, based on sound science, to
allow therapies to begin the path to development. Dis-
cussion between patient groups, biotechnology leaders,
drug developers, and regulatory authorities is essential
to develop clear criteria for rare or ultra-rare diseases,
detailing necessary features of a usable surrogate end-
point that will protect patients and guide early research
toward providing the needed information. Clear criteria
are also essential to biotechnology companies and inves-
tors since only a high degree of certainty regarding the
feasibility of a surrogate-endpoint driven pivotal study
will increase the incentive to initiate development pro-
grams in many rare diseases. If a reasonable guidance
were provided which defines scientifically-sound surro-
gates and achievable qualification criteria for the AA
pathway to biotechnology companies, investors, and
patients alike, rare disease drug development could
potentially grow many fold as renewed biotechnology
investment becomes plausible. Difficult and tragic dis-
eases will then finally have a chance to be treated based
on cutting-edge science.
Conclusion
By highlighting fifteen ultra-rare disease examples, we
have demonstrated the existence of promising, scientifi-
cally-sound animal model therapies that have not yet
been translated to the clinic. We evaluated clinical- or
surrogate-based clinical development programs for these
fifteen diseases and showed that the use of the AA path-
way led to a decrease in cost to approval of 62%, and an
increase in NPV from a mean of $23 M to $72 M. For
the same biotechnology company investment, three
t i m e sa sm a n yu l t r a - r a r ed i s ease drugs could be devel-
oped with AA. Collaboration between academia, govern-
ment, and industry is essential in order to set clear and
p r a c t i c a lr e g u l a t o r yc r i t e r i af o ru s eo fA Ai nu l t r a - r a r e
disease treatment development, accelerating the transla-
tion of science into treatments for ultra-rare disease
patients.
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